Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022
| Title: | Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022 |
|---|---|
| Authors: | Gillessen S; Bossi A; Davis ID; de Bono J; Fizazi K; James ND; Mottet N; Shore N; Small E; Smith M; Sweeney C; Tombal B; Antonarakis ES; Aparicio AM; Armstrong AJ; Attard G; Beer TM; Beltran H; Bjartell A; Blanchard P; Briganti A; Bristow RG; Bulbul M; Caffo O; Castellano D; Castro E; Cheng HH; Chi KN; Chowdhury S; Clarke CS; Clarke N; Daugaard G; De Santis M; Duran I; Eeles R; Efstathiou E; Efstathiou J; Ngozi Ekeke O; Evans CP; Fanti S; Feng FY; Fonteyne V; Fossati N; Frydenberg M; George D; Gleave M; Gravis G; Halabi S; Heinrich D; Herrmann K; Higano C; Hofman MS; Horvath LG; Hussain M; Jereczek-Fossa BA; Jones R; Kanesvaran R; Kellokumpu-Lehtinen PL; Khauli RB; Klotz L; Kramer G; Leibowitz R; Logothetis CJ; Mahal BA; Maluf F; Mateo J; Matheson D; Mehra N; Merseburger A; Morgans AK; Morris MJ; Mrabti H; Mukherji D; Murphy DG; Murthy V; Nguyen PL; Oh WK; Ost P; O'Sullivan JM; Padhani AR; Pezaro C; Poon DMC; Pritchard CC; Rabah DM; Rathkopf D; Reiter RE; Rubin MA; Ryan CJ; Saad F; Pablo Sade J; Sartor OA; Scher HI; Sharifi N; Skoneczna I; Soule H; Spratt DE; Srinivas S; Sternberg CN; Steuber T; Suzuki H; Sydes MR; Taplin ME; Tilki D; Türkeri L; Turco F; Uemura H; Ürün Y; Vale CL; van Oort I; Vapiwala N; Walz J; Yamoah K; Ye D; Yu EY; Zapatero A; Zilli T; Omlin A. |
| Contributors: | Gillessen, S; Bossi, A; Davis, Id; De Bono, J; Fizazi, K; James, Nd; Mottet, N; Shore, N; Small, E; Smith, M; Sweeney, C; Tombal, B; Antonarakis, E; Aparicio, Am; Armstrong, Aj; Attard, G; Beer, Tm; Beltran, H; Bjartell, A; Blanchard, P; Briganti, A; Bristow, Rg; Bulbul, M; Caffo, O; Castellano, D; Castro, E; Cheng, Hh; Chi, Kn; Chowdhury, S; Clarke, C; Clarke, N; Daugaard, G; De Santis, M; Duran, I; Eeles, R; Efstathiou, E; Efstathiou, J; Ngozi Ekeke, O; Evans, Cp; Fanti, S; Feng, Fy; Fonteyne, V; Fossati, N; Frydenberg, M; George, D; Gleave, M; Gravis, G; Halabi, S; Heinrich, D; Herrmann, K; Higano, C; Hofman, M; Horvath, Lg; Hussain, M; Jereczek-Fossa, Ba; Jones R; Kanesvaran, R; Kellokumpu-Lehtinen, Pl; Khauli, Rb; Klotz, L; Kramer, G; Leibowitz R; Logothetis, Cj; Mahal, Ba; Maluf, F; Mateo, J; Matheson, D; Mehra, N; Merseburger A; Morgans, Ak; Morris, Mj; Mrabti, H; Mukherji, D; Murphy, Dg; Murthy, V; Nguyen, Pl; Oh, Wk; Ost, P; O'Sullivan, Jm; Padhani, Ar; Pezaro, C; Poon, Dmc; Pritchard, Cc; Rabah DM; Rathkopf, D; Reiter, Re; Rubin, Ma; Ryan, Cj; Saad, F; Pablo Sade, J; Sartor, Oa; Scher, Hi; Sharifi, N; Skoneczna, I; Soule, H; Spratt, De; Srinivas, S; Sternberg, Cn; Steuber, T; Suzuki, H |
| Publication Year: | 2023 |
| Collection: | Università degli Studi di Trento: CINECA IRIS |
| Subject Terms: | Prostate cancer; Locally advanced prostate cancer; Biochemical recurrence; Side effect; Hormonal treatment; Next-generation imaging; Prostate-specific membrane; antigen positron emission; tomography imaging; Adjuvant therapy; Salvage therapy; Salvage radiation therapy |
| Description: | Background: Innovations in imaging and molecular characterisation and the evolution of new therapies have improved outcomes in advanced prostate cancer. Nonetheless, we continue to lack high-level evidence on a variety of clinical topics that greatly impact daily practice. To supplement evidence-based guidelines, the 2022 Advanced Prostate Cancer Consensus Conference (APCCC 2022) surveyed experts about key dilemmas in clinical management. Objective: To present consensus voting results for select questions from APCCC 2022. Design, setting, and participants: Before the conference, a panel of 117 international prostate cancer experts used a modified Delphi process to develop 198 multiplechoice consensus questions on (1) intermediate- and high-risk and locally advanced prostate cancer, (2) biochemical recurrence after local treatment, (3) side effects from hormonal therapies, (4) metastatic hormone-sensitive prostate cancer, (5) nonmetastatic castration-resistant prostate cancer, (6) metastatic castration-resistant prostate cancer, and (7) oligometastatic and oligoprogressive prostate cancer. Before the conference, these questions were administered via a web-based survey to the 105 physician panel members (‘‘panellists’’) who directly engage in prostate cancer treatment decision-making. Herein, we present results for the 82 questions on topics 1–3. Outcome measurements and statistical analysis: Consensus was defined as 75% agreement, with strong consensus defined as 90% agreement. Results and limitations: The voting results reveal varying degrees of consensus, as is discussed in this article and shown in the detailed results in the Supplementary material. The findings reflect the opinions of an international panel of experts and did not incorporate a formal literature review and meta-analysis. Conclusions: These voting results by a panel of international experts in advanced prostate cancer can help physicians and patients navigate controversial areas of clinical management for which high-level ... |
| Document Type: | article in journal/newspaper |
| Language: | English |
| Relation: | info:eu-repo/semantics/altIdentifier/wos/WOS:000982368200001; volume:2023/83; issue:3; firstpage:267; lastpage:293; numberofpages:27; journal:EUROPEAN UROLOGY; https://hdl.handle.net/11572/478190; https://www.sciencedirect.com/science/article/pii/S0302283822027890?via=ihub |
| DOI: | 10.1016/j.eururo.2022.11.002 |
| Availability: | https://hdl.handle.net/11572/478190; https://doi.org/10.1016/j.eururo.2022.11.002; https://www.sciencedirect.com/science/article/pii/S0302283822027890?via=ihub |
| Rights: | info:eu-repo/semantics/openAccess ; license:Creative commons ; license uri:http://creativecommons.org/licenses/by-nc-nd/4.0/ |
| Accession Number: | edsbas.2D2A5388 |
| Database: | BASE |